49,294
edits
Difference between revisions of "Standarized uptake value"
Jump to navigation
Jump to search
Standarized uptake value (view source)
Revision as of 15:07, 28 November 2023
, 15:07, 28 November 2023no edit summary
(create) |
|||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Standardized uptake value''', abbreviated '''SUV''', is a semi-quantitative measure in PET | '''Standardized uptake value''', abbreviated '''SUV''', is a semi-quantitative measure in [[PET scan]]s. | ||
:<math>SUV = \frac {c(t)}{injected\ dose(t_0) \quad / \quad body\ weight}</math> | :<math>SUV = \frac {c(t)}{injected\ dose(t_0) \quad / \quad body\ weight}</math> | ||
==Non-small cell lung cancer== | |||
{{Main|Non-small cell lung cancer}} | |||
*The SUV of fluorine-18 fluorodeoxyglucose of the primary tumour is a predictor of lymph node metastases in a multivariate analysis.<ref name=pmid24535381>{{Cite journal | last1 = Xu | first1 = ZQ. | last2 = Xie | first2 = LJ. | last3 = Fan | first3 = W. | last4 = Duan | first4 = XB. | last5 = Cheng | first5 = MH. | title = Risk factors for mediastinal lymph node metastasis in non-small-cell lung cancer by PET/CT. | journal = Nucl Med Commun | volume = 35 | issue = 5 | pages = 466-71 | month = May | year = 2014 | doi = 10.1097/MNM.0000000000000077 | PMID = 24535381 }}</ref> | |||
**Cut-off: 9.3. | |||
***[[Sensitivity]] ~75%. | |||
***[[Specificity]] ~54%. | |||
*The ratio of the ''SUV node/SUV primary tumour (SUV<sub>N</sub>/SUV<sub>T</sub>)'' is better predictor than the ''maximal (node) SUV (SUV<sub>max</sub>)''.<ref name=pmid26163919>{{Cite journal | last1 = Mattes | first1 = MD. | last2 = Moshchinsky | first2 = AB. | last3 = Ahsanuddin | first3 = S. | last4 = Rizk | first4 = NP. | last5 = Foster | first5 = A. | last6 = Wu | first6 = AJ. | last7 = Ashamalla | first7 = H. | last8 = Weber | first8 = WA. | last9 = Rimner | first9 = A. | title = Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer. | journal = Clin Lung Cancer | volume = | issue = | pages = | month = Jun | year = 2015 | doi = 10.1016/j.cllc.2015.06.001 | PMID = 26163919 }}</ref> | |||
**Cut-off: 0.28. | |||
***Sensitivity 90%. | |||
***Specificity 68%. | |||
==See also== | ==See also== | ||
*[[Oncology]]. | *[[Oncology]]. | ||
*[[Positron emission tomography]]. | |||
==References== | |||
{{Reflist|1}} | |||
==External links== | ==External links== | ||